ephb4-hsa fusion protein
Recombinant proteinexperimental
Clinical trial activity
11 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Sep 6, 2012 (NCT01642342)
Timeline
Indications
Studied for
- Bone Marrow Cells · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 2/Phase 3
- Castration · Phase 2
- Cholangiocarcinoma · Phase 1
- Gallbladder Neoplasms · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Mutation · Phase 2
- Myeloproliferative Disorders · Phase 1
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Sarcoma, Kaposi · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Testosterone · Phase 2
- Urinary Bladder Neoplasms · Phase 2/Phase 3
Mechanism of action
- Ephrin type-B receptor 4INHIBITOR
EPHB4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- albumin fusion protein sephb4-hsa
- ephb4-hsa fusion protein
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06493552 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2024 | University of Southern California, Vasgene Therapeutics, Inc |
| NCT04033432 | Phase 2 | Sep 3, 2019 | National Cancer Institute (NCI), Northwestern University, Vasgene Therapeutics, Inc |
| NCT03993106 | Phase 2 | Jul 31, 2019 | AIDS Healthcare Foundation, Vasgene Therapeutics, Inc |
| NCT03552796 | Phase 1 | Oct 22, 2018 | National Cancer Institute (NCI), University of Southern California |
| NCT03519984 | Phase 1 | May 9, 2018 | L K Whittier Foundation, National Cancer Institute (NCI), University of Southern California, Vasgene Therapeutics, Inc |
| NCT03049618 | Phase 2 | Mar 10, 2017 | National Cancer Institute (NCI), University of Southern California |
| NCT02717156 | Phase 2 | Nov 21, 2016 | National Cancer Institute (NCI), University of Southern California |
| NCT02767921 | Phase 1 | Aug 2, 2016 | National Cancer Institute (NCI), University of Southern California |
| NCT02799485 | Phase 2 | Nov 1, 2015 | AIDS Malignancy Consortium, Hoosier Cancer Research Network, National Cancer Institute (NCI), The EMMES Corporation, Vasgene Therapeutics, Inc |
| NCT02495896 | Phase 1 | Sep 1, 2015 | National Cancer Institute (NCI), University of Southern California, Vasgene Therapeutics, Inc |
| NCT01642342 | Phase 1 | Sep 6, 2012 | National Cancer Institute (NCI), University of Southern California, Vasgene Therapeutics, Inc, V Foundation |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 9 | 0 | 2 | 2012 |
| University of Southern California | Academic/Hospital | 8 | 7 | 3 | 2012 |
| Vasgene Therapeutics, Inc | For profit | 7 | 2 | 3 | 2012 |
| AIDS Healthcare Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
| AIDS Malignancy Consortium | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 0 | 1 | 2015 |
| L K Whittier Foundation | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2015 |
| V Foundation | Academic/Hospital | 1 | 0 | 1 | 2012 |
10 organizations
Page 1 / 1